GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
Stock · NYSE · Health Care
$50.82as of 8/28/2026
Price chart
Open in TradingViewActive signals
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 66,841
- Website
- www.gsk.com/
Fundamentals
- 1-day range
- $49.96$50.88
- Market cap
- $104.31B
- P/E (trailing)
- 15.53
- P/E (forward)
- 10.19
- EPS (trailing)
- $1.18
- Dividend yield
- 3.92%
- Beta
- 1.25
- Avg. volume
- 3.92M
- Ex-dividend date
- August 14, 2026
- Dividend pay date
- October 8, 2026
Forecasts
8 analyst ratings
GSK plc American Depositary Shares (Each representing two Ordinary Shares) Competitors
Chosen by industry and closest market cap.
- GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)$50.82▲ 1.09%Market cap $104.31BP/E 15.53$1,441$2,282
- SNYSanofi ADS$44.82▼ 0.04%Market cap $104.75BP/E 16.24$71.25$91.15
- VRTXVertex Pharmaceuticals Incorporated Common Stock$541.72▼ 1.06%Market cap $119.47BP/E 30.70$374.17$555.69
- PFEPfizer Inc. Common Stock$27.95▼ 0.25%Market cap $142.66BP/E 35.19$23.58$28.75
- ONCBeOne Medicines Ltd. American Depositary Shares$366.79▼ 1.53%Market cap $34.88BP/E 88.12$205.51$346
- ZTSZoetis Inc. Class A Common Stock$77.36▲ 3.12%Market cap $32.32BP/E 11.54$71$156.49
- ROIVRoivant Sciences Ltd. Common Shares$34.71▼ 7.64%Market cap $24.08BP/E —$11.85$37.97
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GSK GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $104.31B | 15.53 | $50.82 | ▲ 1.09% | $1,441$2,282 |
| SNY Sanofi ADS | $104.75B | 16.24 | $44.82 | ▼ 0.04% | $71.25$91.15 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $119.47B | 30.70 | $541.72 | ▼ 1.06% | $374.17$555.69 |
| PFE Pfizer Inc. Common Stock | $142.66B | 35.19 | $27.95 | ▼ 0.25% | $23.58$28.75 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $34.88B | 88.12 | $366.79 | ▼ 1.53% | $205.51$346 |
| ZTS Zoetis Inc. Class A Common Stock | $32.32B | 11.54 | $77.36 | ▲ 3.12% | $71$156.49 |
| ROIV Roivant Sciences Ltd. Common Shares | $24.08B | — | $34.71 | ▼ 7.64% | $11.85$37.97 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- GSK: Still One Of My Top Healthcare PicksSeekingAlpha · 8/27/2026
- FDA Approves Drug To Treat HIV Infection in NewbornsBenzinga · 8/25/2026
- Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease?Benzinga · 8/25/2026
- Dr. Oz Says The MMR Vaccine Is Not 'Lethal' as Trump Administration Faces Questions Over Vaccine Policybenzinga · 8/24/2026
- Dr. Oz Says The MMR Vaccine Is Not 'Lethal' as Trump Administration Faces Questions Over Vaccine PolicyBenzinga · 8/24/2026
- Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine AdvanceSeekingAlpha · 8/20/2026
- 9 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 8/14/2026
- Wall Street Lunch: Trump's MMR Split Plan Faces FDA, Manufacturing HurdlesSeekingAlpha · 8/13/2026
- Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend YieldsBenzinga · 8/11/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 378.40M
- Total value held
- $19.13B
- Institutional holders
- 1024
- Unknown67.66M
- Unknown58.66M
- Unknown34.52M
- Unknown25.20M
- Unknown11.80M
- Unknown11.72M
- Unknown11.03M
- Unknown10.29M
- Unknown9.04M
- Unknown7.51M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 30, 2026
GSK in Focus as FDA Greenlights Newborn HIV Drug Amid Vaccine Debate. GSK recently received approval from the U.S. Food and Drug Administration for a new drug designed to treat HIV infections in newborns, expanding the company's pediatric portfolio. The news comes during a broader public discussion around vaccine policy, with figures such as Dr. Oz publicly defending the safety of the MMR vaccine as measles cases draw renewed attention in the United States. These developments highlight GSK's involvement in both infectious disease treatment and the wider vaccine conversation. Investors continue to note the company's established position in the healthcare sector.